Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29692898 | 0.84 | GNPAT (0.44) | FOLH1CPB2 | |
| SCHEMBL28528291 | 0.82 | FOLH1 (0.50) | FOLH1CPB2SLC6A5GSRERAP2 | |
| SCHEMBL28528289 | 0.82 | FOLH1 (0.50) | FOLH1CPB2SLC6A5GSRERAP2 | |
| SCHEMBL29379421 | 0.81 | ALDH1A1 (0.46) | FOLH1ALDH1A1MAPTPTGS1 | |
| SCHEMBL24765399 | 0.80 | FOLH1 (0.54) | FOLH1CPB2SLC6A5GSRRNPEP | |
| SCHEMBL1711242 | 0.80 | FOLH1 (0.57) | FOLH1CPB2SLC6A5GSRERAP2 | |
| SCHEMBL29511099 | 0.80 | FOLH1 (0.57) | FOLH1CPB2SLC6A5GSRERAP2 | |
| SCHEMBL30861836 | 0.80 | MAPT (0.52) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL29368554 | 0.80 | FOLH1 (0.57) | FOLH1CPB2SLC6A5GSRERAP2 | |
| SCHEMBL29563714 | 0.80 | FOLH1 (0.57) | FOLH1CPB2SLC6A5GSRERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478311-B1 | STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION | UNIV CALIFORNIA (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20250388619-A1 | VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE | BIO SYNTHESIS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3596102-B1 | STRUCTURE-BASED PEPTIDE INHIBITORS THAT TARGET THE TAU VQIINK FIBRILLIZATION SEGMENT | UNIV CALIFORNIA (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4441082-A1 | INHIBITORY PEPTIDES FOR THE DIAGNOSTIC AND/OR TREATMENT OF TAUOPATHIES | Université de Rennes (FR) | 2024-10-09 | — | — | EP | disclosed |
| CN-116650617-A | Structure-based peptide inhibitors of alpha-synuclein aggregation | 加利福尼亚大学董事会 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023099560-A1 | INHIBITORY PEPTIDES FOR THE DIAGNOSTIC AND/OR TREATMENT OF TAUOPATHIES | UNIVERSITE DE RENNES (FR) | 2023-06-08 | — | — | WO | disclosed |
| EP-4186918-A1 | INHIBITORY PEPTIDES FOR THE DIAGNOSTIC AND/OR TREATMENT OF TAUOPATHIES | Université de Rennes (FR) | 2023-05-31 | — | — | EP | disclosed |
| US-20230069905-A1 | STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-09 | — | — | US | disclosed |
| US-11565240-B2 | Mixed mode affinity chromatography carrier | FUJIFILM CORPORATION (JP) | 2023-01-31 | — | — | US | disclosed |
| US-11390646-B2 | Structure-based peptide inhibitors of α-synuclein aggregation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390646-B2 | Structure-based peptide inhibitors of α-synuclein aggregation | SNCA, PARK7, IAPP | FOLH1 1643/4885CPB2 922/4885ALDH1A1 4543/4885 |
| US-20230069905-A1 | STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION | SNCA, PARK7, IAPP | FOLH1 1623/4885CPB2 843/4885ALDH1A1 4530/4885 |
| US-20250388619-A1 | VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE | RNMT, ADAR, RNGTT | FOLH1 2418/4885CPB2 4278/4885ALDH1A1 4823/4885 |
| US-11565240-B2 | Mixed mode affinity chromatography carrier | FCGR2A, FCGR3B, FCGR1A | FOLH1 368/4885CPB2 301/4885ALDH1A1 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.